Remicade (infliximab) reduces signs and symptoms of ulcerative colitis, inducing and maintaining clinical remission in these patients.
Remicade belongs to a class of drugs called tumor necrosis factor blockers, which suppress the immune system by blocking the activity of TNF, a substance that can cause inflammation and lead to autoimmune diseases.
Related Articles on Ulcerative Colitis:
Study: New Cytokine Provides Protection From Colitis
Study: P53, PUMA Independently Regulate IEC Apoptosis in Colitis
FDA Approves Wider Use of Lialda for Patients With Ulcerative Colitis
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.